To promote progress in this area, it is time to develop new AEP inhibitors or candidate drugs with acceptable druggability to perform translational research, and invent advanced AEP-targeted imaging probes to evaluate the predictive efficacy of brain AEP imaging as a biomarker for preclinical AD, particularly in a real-world setting. The gene discussed is LGMN; the disease is Alzheimer disease.